On the other hand, there is an ongoing phase II-III trial (NCT03130790) that attempts to explore the therapeutic efficacy and safety of frontline varlitinib plus folinic acid-leucovorin-fluorouracil-oxaliplatin (mFOLFOX6, interventional group) versus placebo plus mFOLFOX6 (placebo group) in patients with chemo-naïve advanced or metastatic HER1- and HER2-positive coexpressing GC [34]. This evidence concerns the gene ERBB2 and gastric cancer.